Lymphoma Clinical Trials in Beijing
42 recruitingBeijing, China
Showing 1–20 of 42 trials
Recruiting
Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Untreated Follicular Lymphoma
AstraZeneca1,018 enrolled135 locationsNCT06549595
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Hoffmann-La Roche300 enrolled12 locationsNCT07200375
Recruiting
Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Hoffmann-La Roche182 enrolled75 locationsNCT06084936
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 2
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China30 enrolled14 locationsNCT07441993
Recruiting
Phase 3
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Large B-cell Lymphoma
AstraZeneca420 enrolled40 locationsNCT07215585
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca276 enrolled63 locationsNCT06564038
Recruiting
Phase 1Phase 2
Evaluate the Safety and Clinical Activity of HH2853
Advanced Solid TumorPeripheral T Cell LymphomaFL Lymphoma+1 more
Haihe Biopharma Co., Ltd.254 enrolled25 locationsNCT04390737
Recruiting
Phase 1
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
Advanced Solid TumorNon-Hodgkin Lymphoma
Axter Therapeutics (Beijing) Co., Ltd78 enrolled5 locationsNCT06484985
Recruiting
Phase 2
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting
Phase 4
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Marginal Zone Lymphoma (MZL)
Beijing Tongren Hospital88 enrolled3 locationsNCT07355699
Recruiting
Phase 2
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital100 enrolled1 locationNCT06393361
Recruiting
Phase 1Phase 2
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.112 enrolled15 locationsNCT05800977
Recruiting
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Non-Hodgkin's LymphomaMycosis Fungoides
Stanford University2,000 enrolled13 locationsNCT02848274
Recruiting
Phase 1Phase 2
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Diffuse Large B Cell Lymphoma
Dizal Pharmaceuticals150 enrolled16 locationsNCT07059650
Recruiting
Phase 1Phase 2
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Non-Hodgkin's Lymphoma
Chinese PLA General Hospital30 enrolled2 locationsNCT05554939
Recruiting
Phase 1Phase 2
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
T-cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital36 enrolled3 locationsNCT07022964
Recruiting
Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
LymphomaMDSLeukemia
Peking University First Hospital24 enrolled1 locationNCT06895538
Recruiting
Not Applicable
One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
B-Cell Non-Hodgkin Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-Refractory
Beijing GoBroad Hospital8 enrolled1 locationNCT06618313